00:49 , Nov 10, 2017 |  BC Innovations  |  Product R&D

Blueprint gets the GIST

Blueprint is positioning its kinase inhibitor BLU-285 to take a dominant position in gastrointestinal tumors, with preclinical and Phase I data showing the compound inhibits not only mutant forms of c-Kit and PDGFRA that underlie...
23:38 , Nov 21, 2016 |  BioCentury  |  Strategy

LG’s biotech legacy

LG Life Sciences Ltd. was a pioneer, producing the first globally approved drugs developed by a South Korean company. A shift in priorities all but stopped the flow of innovative new drugs to the world...
07:00 , Jul 31, 2014 |  BC Innovations  |  Translation in Brief

Translational tidbits

Benjamin Boettner, Associate Editor, and Chris Cain, Michael J. Haas and Kai-Jye Lou, Senior Writers  Quantitative boost for CSHL The Simons Foundation has donated $50 million to Cold Spring Harbor Laboratory to establish the Simons...
07:00 , Aug 8, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Colorectal cancer; colitis c-Src tyrosine kinase (CSK) Mouse studies suggest activating CSK could help treat colitis and colon cancer. In a mouse model for chemical-induced...
07:00 , Mar 29, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Autoimmune disease Protein tyrosine phosphatase non-receptor type 22 (PTPN22; LYP) In vitro studies identified a LYP inhibitor that could help...
08:00 , Mar 5, 2012 |  BioCentury  |  Finance

Putting debt to work

It's notoriously difficult for development-stage public biotechs in Asia to raise enough money to support their clinical programs. To get around the problem, Japan's NanoCarrier Co. Ltd. and Korea's CrystalGenomics Inc. have turned to debt...
08:00 , Feb 20, 2012 |  BC Week In Review  |  Financial News

NanoCarrier proposes convertible bond financing

NanoCarrier Co. Ltd. (Tokyo:4571), Chiba, Japan   Business: Drug delivery, Cancer   Date announced: 1/26/12   Type: Convertible bond financing   To be raised: Up to ¥1.7 billion ($21.9 million)   Investors: Whiz Partners; CSK...
01:40 , Feb 17, 2012 |  BC Extra  |  Financial News

NanoCarrier to raise $47.7 million

NanoCarrier Co. Ltd. (Tokyo:4571) is planning to raise Y3.7 billion ($47.7 million) through the sale of convertible bonds and stock options to Whiz Partners and CSK Venture Capital. The offerings are contingent on shareholder approval...
07:00 , Sep 13, 2010 |  BioCentury  |  Finance

Regulatory milestones

Forest Laboratories Inc. (NYSE:FRX) gained $0.18 to $29.74 last week after FDA's Anti-Infective Drugs Advisory Committee voted unanimously that ceftaroline was a safe and effective treatment for community-acquired bacterial pneumonia (CABP) and complicated skin and...
08:00 , Jan 11, 2010 |  BC Week In Review  |  Financial News

Microchips completes venture financing

MicroChips Inc. , Cambridge, Mass.   Business: Drug delivery   Date completed: 1/7/10   Type: Venture financing   Raised: $16.5 million   Investors: Polaris Venture Partners; Novartis Venture Funds; Flybridge Capital Partners; Medtronic; Saints Capital;...